These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20219265)

  • 1. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
    Menter A; Augustin M; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani P
    J Am Acad Dermatol; 2010 May; 62(5):812-8. PubMed ID: 20219265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
    J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A; Tyring SK; Gordon K; Kimball AB; Leonardi CL; Langley RG; Strober BE; Kaul M; Gu Y; Okun M; Papp K
    J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB; Yu AP; Signorovitch J; Xie J; Tsaneva M; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
    J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
    Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.